admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

GH Research Reports First Quarter 2022 Financial Results and Provides Business...

COMPASS Pathways presents largest ever study of psilocybin therapy, at American...

Incannex announces positive results from phase 2 clinical trial investigating the...

PT330 – Dick Simon – Researching Ethnobotanical Efficacy and the Search...

Exploring Ketamine’s Antimicrobial Effects & Fungal Sources: Part 2

PT329 – Dr. Scott Shannon – The Board of Psychedelic Medicine...

Psychedelic Bulletin #107 – Call for Proposals: Opinions Column; How to...

PT328 – Courtney Watson, LMFT – Ancestral Veneration and Psychedelic-Assisted Therapy...

Exploring Ketamine’s Antimicrobial Effects & Fungal Sources: Part 1

PT327 – Rick Doblin, Ph.D. – Confronting Abuse in Clinical Trials...

1...141142143...218 Page 142 of 218

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin